Abstract:The burden of chronic liver disease is globally increasing at an alarming rate. Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer, and mortality. LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs). In the healthy liver, quiescent HSCs metabolize and store retinoids. Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts; lose their vitamin A; upregulate α-smooth muscle actin; and produce proinflammatory soluble mediators, collagens, and inhibitors of ECM degradation. Activated HSCs are the main effector cells during hepatic fibrogenesis. In addition, the accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival. The main source of myofibroblasts is resident HSCs. Activated HSCs migrate to the site of active fibrogenesis to initiate the formation of a fibrous scar. Single-cell technologies revealed that quiescent HSCs are highly homogenous, while activated HSCs/myofibroblasts are much more heterogeneous. The complex process of inflammation results from the response of various hepatic cells to hepatocellular death and inflammatory signals related to intrahepatic injury pathways or extrahepatic mediators. Inflammatory processes modulate fibrogenesis by activating HSCs and, in turn, drive immune mechanisms via cytokines and chemokines. Increasing evidence also suggests that cellular stress responses contribute to fibrogenesis. Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells. However, despite numerous clinical studies on plausible drug candidates, an approved antifibrotic therapy still remains elusive. This state-of-the-art review presents cellular and molecular mechanisms involved in hepatic fibrogenesis and its resolution, as well as comprehensively discusses the drivers linking liver injury to chronic liver inflammation and LF.

Hepatic Stellate Cells as a Target for the Treatment of Liver Fibrosis

The Progression for the Therapy of Liver Fibrosis Targeting to Hepatic Stellate Cells

Hepatic stellate cells: a target for the treatment of liver fibrosis

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

Regulatory Long Non-Coding RNAs of Hepatic Stellate Cells in Liver Fibrosis (Review)

Liver Fibrosis Resolution: from Molecular Mechanisms to Therapeutic Opportunities

Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets

Hepatic stellate cells as key target in liver fibrosis

Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis

New Developments on the Treatment of Liver Fibrosis

Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy

Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis

From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells

Hepatic fibrosis: From bench to bedside

Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies

Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis—Roles as Putative Treatment Targets?

Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis

Molecular and cellular mechanisms of liver fibrosis and its regression

Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis